OCCULOGIX INCORPORATED (NASD: OCCX)
"Up 88.41% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/OCCX.php

OccuLogix, Inc., an ophthalmic therapeutic company, provides treatments for eye diseases. Its treatments primarily include age-related macular degeneration and glaucoma. The company develops RHEO System, which consists of the OctoNova Pump and a disposable treatment set, is designed to improve microcirculation in the eye by filtering high molecular weight proteins and other macromolecules from the patient's plasma. OccuLogix operates in the United States, Canada, Europe, and Israel. The company was founded in 1996 and is headquartered in Mississauga, Canada.

OCCX News:

April 8 - OccuLogix' POC Diagnostics Subsidiary, OcuSense, Achieves ISO 13485:2003 Certification

OccuLogix, Inc. (NASD: OCCX) (Toronto: OC.TO) announced that its point-of-care diagnostics subsidiary, OcuSense, Inc., has received company-wide certification to ISO 13485:2003.

ISO, the International Organization for Standardization, is a worldwide federation of national standards bodies created to set standards for similar technologies in different countries. Details about ISO and its standards can be found at www.iso.org. The ISO 13485:2003 standard specifically focuses on the unique and rigorous requirements for companies involved in the development of medical devices. Achievement of ISO certification marks OcuSense's corporate commitment to quality in the design and manufacture its medical devices.

"The realization of our Beta Prototype along with our ISO certification represent significant milestones toward achieving commercial launch of our first product," commented Eric Donsky, OcuSense's Chairman & CEO. "We are looking forward to scaling commercial manufacturing of our TearLab(TM) Osmolarity System. We expect to attain CE Mark ahead of our initial product launch which is scheduled for 5 EU Countries later this year."

Elias Vamvakas, OccuLogix' Chairman and CEO, said, "The miniaturization of diagnostic devices, reducing costs, increasing throughput and enabling doctors to deliver a higher level of patient care by providing accurate laboratory test results at the point of care, is a growing movement and a major trend within medicine. OcuSense's achievement of ISO accreditation is an important milestone as we look toward our objective of FDA 510K clearance by the end of Q4 2008."

FRONTIER AIRLINES HOLDINGS (NASD: FRNT)
"Up 66.65% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/FRNT.php

Frontier Airlines Holdings, Inc., through its subsidiaries, provides air transportation for passengers and freight. The company operates jet service carriers linking from its Denver, Colorado hub to 46 cities coast-to-coast, 8 cities in Mexico, and 1 city in Canada, as well as provides service from other non-hub cities, including service from 10 non-hub cities to Mexico. As of May 18, 2007 it operated 59 jets, including 49 Airbus A319s and 10 Airbus A318s. The company was founded in 1994 and is headquartered in Denver, Colorado.

FRNT News:

April 11 - Universal Detection Technology Receives Purchase Order for Anthrax Detection Kits From Israeli Security Firm

Frontier Airlines Holdings, Inc. (NASD: FRNT) announced it continues to be fully operational, providing customers with the outstanding service they expect from the Denver-based carrier. On Friday, April 11, 2008, it was business as usual for Frontier customers who were met with friendly service, on-time flight schedules, and hassle-free travel. In its first full day of Chapter 11 bankruptcy protection, Frontier flew a full schedule of 405 flights, with more than 74% of those flights arriving on time, and zero cancellations as of late this afternoon. The airline saw virtually no drop in anticipated numbers, serving a total of 29,088 customers.

"We've been touched by the positive attitude of our employees in Denver and around our system — and by the incredible support shown to us by our customers," said Cliff Van Leuven, Vice President of Customer Service.

Frontier Airlines Holdings, Inc. announced on April 10, 2008 that, following an unexpected attempt by its principal credit card processor to substantially increase a "holdback" of customer receipts, which threatened to severely impact Frontier's liquidity, Frontier and its subsidiaries have filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code.

Frontier intends to continue the exceptional service customers experienced Friday throughout its reorganization process. Specifically, it expects to:

*Operate its full schedule of flights;
*Honor tickets and reservations and provide refunds and exchanges as usual;
*Maintain its EarlyReturns frequent flyer program and other award-winning customer service programs;
*Provide employee wages, healthcare coverage, vacation, sick leave, and similar benefits without interruption; and,
*Pay suppliers for goods and services received during the reorganization process.

More information about Frontier's Chapter 11 filing is available on the Internet at FrontierAirlines.com/restructure. Court filings and claims information are available at http://Chapter11.epiqsystems.com/frontier.

ENZYME ENVIRONMENTAL (OTC: EESO)
"Up 58.82% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/EESO.php

Enzyme Consultants Organization (ECO) is a U.S. based manufacturer of industrial and agricultural enzyme products. All manufacturing, testing, and formulating are conducted in its manufacturing plant, located in Fort Wayne, Indiana. ECO strives to become a leader in ecological friendly or “Green Products” targeting the industrial and agricultural markets. It is our goal to have the best performing products on the market in each industry. Developing a growing and satisfied customer base is our number one marketing strategy.

EESO News:

April 14 - Enzyme Environmental Solutions Completes Acquisition of U.S. Test Site and Verifies Application With Wal-Mart

Enzyme Environmental Solutions Inc. (OTC: EESO) CEO S. Jared Hochstedler announced that the company has signed the "contract for conditional sale of Real Estate" to acquire the test site to continue improving its agricultural odor reduction product. Possession of the property was conveyed upon the contract execution.

Hochstedler commented, "The agriculture industry offers a tremendous opportunity for our shareholders. Right now the USDA does not require odor control here in the United States, but we all are aware of housing developments that have fought to shut down hogging operations due to the offensive odor. We have some larger hog operations right in the Fort Wayne area that have shut down operations because of the complaints of surrounding developments.

"If you can imagine the application of our proprietary enzyme-based formulation for odor reduction (already being shipped to our Korean distributor) also being used to keep the hogs clean, reducing the possibility for disease in the animal itself thus allowing for healthier and greater weight gain, how this would impact the hog operations and margins for the farming community. Couple the odor reduction, improved health of the animals and ability to turn the waste into useable processed fertilizing mulch and this literally could produce potential revenues of over $500 million per year," Hochstedler further commented.

"I know these numbers are staggering and almost inconceivable, but think about it just a little and allow your mind to ponder all of the applications that are possible. I believe our shareholders will understand why I am so excited for our company's potential," stated Hochstedler.

The company would also like to communicate with all shareholders that in 2004, Wal-Mart launched a company-wide sustainability initiative with the goals of generating zero waste, being supplied by 100% renewable energy and to selling products that sustain resources and the environment. EESO has already made application in the past with The Cleantech Group (www.cleantech.com/accelerator) which is serving Wal-Mart (NYSE: WMT) to:

* Communicate to the market their needs to meet these objectives; and
* Assist in identifying technologies and solutions which will generate demonstrable progress towards these goals.

This site will serve as the gateway between solution providers and Wal-Mart. Wal-Mart seeks to identify solutions that can be integrated into their current operations. If a solution appears promising, additional steps will be provided towards a procurement dialog directly with Wal-Mart.

The company would also like to confirm that as of April 10, 2008 the outstanding share count remains at 223,716,398 commons shares issued and outstanding.

AVALON CAPITAL HOLDINGS (OTC: AVAL)
"Up 42.86% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/AVAL.php

Avalon Capital Holdings Corporation, through its subsidiaries, develops, markets, and distributes high-performance trading software to financial institutions that engage in online trading. The Company specializes in products and turnkey solutions related to the Foreign Exchange (”Forex”) market. For additional information, visit www.avaloncapitalholdings.com or e-mail This email address is being protected from spam bots, you need Javascript enabled to view it .

AVAL News:

April 14 - Avalon Capital Holdings Wholly Owned Subsidiary Traders Development, LLC Announces Mutual Marketing Agreement with Hotspot FXr LLC

Avalon Capital Holdings Corporation (OTC: AVAL) wholly owned subsidiary, Traders Development LLC, announced that it has signed a Mutual Marketing Agreement with Hotspot FXr LLC. The agreement was officially signed on December 3, 2007. Pursuant to the Mutual Marketing Agreement, Traders Development, LLC has already signed two licensing agreements with qualified financial companies and expects to earn revenues from these licensees by Q2 2008.

The Mutual Marketing agreement allows Hotspot FXr sales representatives to offer the Avalon FX Pro 4.1 trading platform to potential white label banks and brokerages as part of a Hotspot FX Avalon FX Pro Retail White Label solution. Furthermore, the agreement allows Avalon to introduce qualified financial companies to Hotspot FXr for the purpose of receiving spot Forex liquidity. The Avalon FX Pro(TM) 4.1 Trading Terminal is already connected to Hotspot FXr, one of the largest retail foreign exchange ECN liquidity providers. Furthermore, Avalon has created a specialized platform environment with the Hotspot FXR price feed and Market Depth.

Avalon Capital Holdings CEO Dr. Vladimir Karpenkov said, "Today's announcement is a testimony of our continuous efforts to provide the best retail foreign exchange platform to financial companies and their clients. Hotspot FXr has an experienced team of top-notch sales professionals and we are happy to provide them a phenomenal trading platform to help them grow their Retail Forex business. Hotspot FXr is a leader in the spot Forex landscape. When coupled with our Avalon FX Pro(TM) proprietary trading technology, it offers a top class trading experience for clients."

PLANET NUTRITION HOLDINGS (OTC: PNHL)
"Up 50.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/PNHL.php

Planet Nutrition, Inc. has been in business since 1999 as a retailer of nutritional products and programs in the diet and nutrition industry. By offering a superior product line, employing innovative marketing techniques and developing strategic partnerships with manufacturers and distributors, the company maintains an uncompromising commitment to quality while ensuring the best value to our customers. Visit Planet Nutrition online at www.planetnutritiononline.com.

PNHL News:

April 14 - Planet Nutrition Signs Letter of Intent to Acquire Extreme Fitness

Planet Nutrition Holdings, Inc. (OTC: PNHL) announced that it has signed a letter of intent to acquire Extreme Fitness. Planet Nutrition Holdings Inc., the parent company of Planet Nutrition Inc., a supplement and vitamin company, plans to buy Extreme Fitness, a manufacturer of state of the art fitness equipment.

Extreme Fitness has been in business for over 31 years, manufacturing high quality commercial strength training equipment for 22 years. The main products offered are free weight machines, selectorized machines and a complete line of body weight training equipment that is geared towards, professional, college and high school athletes plus correctional facilities, recreation trails and other forms of outdoor training.

Some of Extreme Fitness customers include the United States Olympic Training Centers in Colorado Springs, Colorado, Lake Placid, New York, San Diego, California, and Salt Lake City, Utah. Professional sports teams include the Tampa Bay Lightning, Boston Celtics, Chicago Bulls, New York Mets, Denver Broncos, New York Giants, and Atlanta Falcons, as well as many professional athletes such as Larry Bird. Extreme has provided equipment for a number of celebrities like Ted Turner, Jane Fonda, Jack Nicklaus, and Randy Travis. Extreme also has provided equipment to many colleges and universities, most recently the U.S. Air Force Academy, and numerous health clubs, such as Gold's and World gyms.

"The resume that Extreme Fitness brings to the table will only improve both companies," stated Dan Starczewski, President and CEO of Planet Nutrition. "Adding a manufacturer of high quality fitness equipment products will allow great synergy for both companies."

PLURISTEM THERAPEUTICS (NASD: PSTI)
"Up 35.21% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/PSTI.php

Pluristem Therapeutics, Inc. engages in the research and development of the mesenchymal and stem cell production technology, and the commercialization of cell therapy products. The company is developing a platform designed to create a functional stem cell production system that can treat severe blood, cardiovascular, autoimmune, and other disorders. It develops PluriX Bioreactor System, which is designed to be a system of stromal cell cultures and substrates that creates an artificial physiological environment where mesenchymal stem cells can grow and reproduce outside of the human body without any use of exogenous biologics or pharmacologicals. The company's principal product, PLX-I is intended to resolve the shortfall of matched tissue for bone marrow transplantation by improving the engraftment of hematopoietic stem cells contained umbilical cord blood. Pluristem's products are derived from mesenchymal stem cells obtained from the placenta and expanded in its proprietary PluriX 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines, or other exogenous materials. The company was founded in 2001 as A.I. Software, Inc. and changed its name to Pluristem Life Systems, Inc. in 2003. Further, it changed its name to Pluristem Therapeutics, Inc. in November 2007. Pluristem Therapeutics is based in Haifa, Israel.

PSTI News:

April 14 - Pluristem's PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model

Pluristem Therapeutics Inc. (NASD: PSTI) (DAX: PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that a preclinical study utilizing the Company’s PLacental eXpanded (PLX) cells showed a statistically significant advantage in ameliorating functional deficiencies in a standard Multiple Sclerosis (MS) animal model. PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.

Researchers at Pluristem utilized the Experimental Autoimmune Encephalitis (EAE) animal model for the study, the paradigm for MS in humans. After EAE was induced, a number of the animals were given PLX cells intravenously while the remaining served as a control. There was a significant reduction in the EAE score in those animals given PLX cells versus the control group and this beneficial effect was seen throughout the 25-day duration of the study. The EAE score is a measurement of functional outcomes in the EAE-afflicted animal and correlates closely with a histological improvement in EAE-induced lesions. Additionally, the beneficial effects were similar to when Zappia et. al. used MSCs that were non-placental in origin in this EAE animal model†.

Zami Aberman, Pluristem’s President and CEO said: “We are very excited that our PLX cells were able to demonstrate beneficial results that are statistically significant in this standardized model for Multiple Sclerosis. These results, in addition to our previously announced PLX STROKE results, demonstrate that PLX cells may be useful in the treatment of central nervous system (CNS) disorders and potentially help millions of people. Additionally, we believe this experiment demonstrates we can potentially utilize our off-the-shelf, easy to obtain PLX cells and achieve results that are as good as or better than MSCs obtained from other more difficult to find sources.”

†Zappia et. al. Mesenchymal stem cells ameliorate experimental autoimmune encephalitis inducing T cell anergy. Blood. 2005;106: 1755-1761

ABOUT MULTIPLE SCLEROSIS (MS)

Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminate, is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. Myelin is the insulating sheath that surrounds nerve cells (neurons). MS may cause numerous physical and mental symptoms, and often progresses to physical and cognitive disability. The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from MS, which represents a current market of approximately $5.4 billion for disease-modifying agents to treat the disorder.